tiprankstipranks
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) AI Stock Analysis

Compare
214 Followers

Top Page

BO

Bolt Biotherapeutics

(NASDAQ:BOLT)

46Neutral
Bolt Biotherapeutics faces significant challenges with ongoing financial losses and cash flow inefficiencies. Although the balance sheet shows a stable equity position and low debt, the lack of profitability and negative valuation metrics significantly impact the stock's attractiveness. Technical analysis shows a bearish trend, adding further pressure on the stock's outlook.
Positive Factors
Clinical Data
Initial Ph 1 dose-escalation data for BDC-3042 at AACR is expected to reveal encouraging clinical signals, including a favorable safety profile and evidence of pharmacodynamic engagement.
Clinical Development
Bolt Biotherapeutics has made encouraging progress on their two lead assets, BDC-3042 and BDC-4182.
Negative Factors
Clinical Trials
The stock is expected to remain pressured until clinical trials play out in 2025.
Financial Performance
Bolt reported 4Q24 revenue of $0.0M and EPS of ($0.42), compared to estimates of $0.9M and ($0.34), respectively.

Bolt Biotherapeutics (BOLT) vs. S&P 500 (SPY)

Bolt Biotherapeutics Business Overview & Revenue Model

Company DescriptionBolt Biotherapeutics (BOLT) is a biotechnology company that operates in the healthcare sector, focusing on developing targeted therapies for cancer treatment. The company leverages its proprietary Boltbody™ platform to create immune-stimulating antibody conjugates (ISACs) designed to engage and activate the immune system to treat tumors. Bolt Biotherapeutics' core products are in various stages of clinical development, aiming to offer innovative solutions for patients with limited treatment options.
How the Company Makes MoneyBolt Biotherapeutics makes money primarily through the development and commercialization of its proprietary cancer therapies. The company's revenue model includes potential milestone payments and royalties from licensing agreements and partnerships with larger pharmaceutical companies. These collaborations help in the advancement of its drug candidates through clinical trials and regulatory approval processes. Additionally, Bolt may secure funding through equity offerings, grants, or government contracts to support its research and development activities. The company's earnings are influenced by the successful progression and commercialization of its drug pipeline.

Bolt Biotherapeutics Financial Statement Overview

Summary
Bolt Biotherapeutics is navigating through losses with some signs of revenue growth, but profitability remains a significant challenge. The company's balance sheet presents a low debt burden and a stable equity position, yet it struggles with cash flow inefficiencies. Continued focus on improving operational efficiencies and strategic financial management is essential to enhance overall financial health.
Income Statement
45
Neutral
Bolt Biotherapeutics shows a modest revenue growth with a 34.3% increase from 2022 to 2023 and a slight decline of 2.4% from 2023 to 2024. However, the company has been experiencing significant losses with a negative net profit margin of -820.7% in 2024. The gross profit margin is stable at 100% for 2024, indicating that cost of goods sold is negligible compared to revenue, but high operational expenses continue to weigh down profitability.
Balance Sheet
55
Neutral
The company maintains a relatively low debt-to-equity ratio of 0.44 in 2024, suggesting a conservative leverage approach. However, return on equity remains negative due to consistent losses, indicating inefficiencies in generating returns for shareholders. The equity ratio stands at 57.4%, reflecting a stable financial structure with more than half of its assets funded by equity.
Cash Flow
50
Neutral
Operating cash flow remains negative, but improved slightly from -69.5 million in 2023 to -61.3 million in 2024. Free cash flow also increased marginally to -61.3 million, indicating ongoing challenges in cash generation. The operating cash flow to net income ratio of 0.97 suggests that cash flow is closely aligned with net losses, while free cash flow to net income ratio mirrors this trend.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
7.69M7.88M5.73M1.26M231.00K
Gross Profit
7.69M5.99M838.00K-2.41M-40.13M
EBIT
-73.05M-76.20M-90.32M-92.79M-49.18M
EBITDA
-66.45M-74.34M-88.66M-91.59M-48.57M
Net Income Common Stockholders
-63.12M-69.20M-85.88M-104.39M-72.27M
Balance SheetCash, Cash Equivalents and Short-Term Investments
47.32M102.19M168.89M186.22M22.84M
Total Assets
99.63M159.78M227.81M307.72M46.54M
Total Debt
25.21M20.22M22.61M24.36M10.88M
Net Debt
18.00M9.41M13.37M-3.03M5.33M
Total Liabilities
42.43M47.04M56.30M57.60M151.49M
Stockholders Equity
57.20M112.74M171.51M250.12M-104.95M
Cash FlowFree Cash Flow
-61.33M-69.73M-78.46M-59.40M-50.57M
Operating Cash Flow
-61.29M-69.53M-76.50M-57.07M-47.31M
Investing Cash Flow
57.58M71.04M57.86M-232.20M-20.59M
Financing Cash Flow
108.00K253.00K503.00K311.11M39.60M

Bolt Biotherapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.38
Price Trends
50DMA
0.46
Negative
100DMA
0.51
Negative
200DMA
0.60
Negative
Market Momentum
MACD
-0.02
Positive
RSI
33.52
Neutral
STOCH
17.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.46, and below the 200-day MA of 0.60, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 33.52 is Neutral, neither overbought nor oversold. The STOCH value of 17.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLT.

Bolt Biotherapeutics Risk Analysis

Bolt Biotherapeutics disclosed 64 risk factors in its most recent earnings report. Bolt Biotherapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Bolt Biotherapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
48
Neutral
$6.86B1.11-50.22%2.47%16.71%1.53%
48
Neutral
$1.09B-57.48%13698.99%31.46%
46
Neutral
$15.34M-74.28%-2.36%9.68%
46
Neutral
$50.42M-273.36%194.23%45.50%
45
Neutral
$538.30M49.633.73%188.64%
42
Neutral
$90.54M-54.21%-78.55%-0.92%
42
Neutral
$11.01M-151.46%-95.23%-325.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BOLT
Bolt Biotherapeutics
0.40
-0.95
-70.37%
FATE
Fate Therapeutics
0.77
-6.24
-89.02%
IOVA
Iovance Biotherapeutics
3.54
-10.47
-74.73%
AFMD
Affimed
0.71
-5.95
-89.34%
ADAP
Adaptimmune Therapeutics
0.30
-1.08
-78.26%
IMTX
Immatics
4.17
-6.37
-60.44%

Bolt Biotherapeutics Corporate Events

Executive/Board Changes
Bolt Biotherapeutics Announces Board Changes and Appointments
Neutral
Dec 23, 2024

Dr. Mahendra Shah resigned from Bolt Biotherapeutics’ Board of Directors, effective December 31, 2024, for personal reasons. Following his resignation, Dr. Jakob Dupont was appointed to the Audit Committee and the Nominating and Corporate Governance Committee, ensuring continuity in the company’s governance.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.